Pharmaceutical – IMI Site http://imisite.org/ Fri, 17 Dec 2021 06:09:09 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://imisite.org/wp-content/uploads/2021/05/imi-site-icon-150x150.png Pharmaceutical – IMI Site http://imisite.org/ 32 32 Carlyle: Reaches Definitive Agreement for Sale of Sunsho Pharmaceutical Co., Ltd. to Towa Pharmaceutical Co., Ltd. https://imisite.org/carlyle-reaches-definitive-agreement-for-sale-of-sunsho-pharmaceutical-co-ltd-to-towa-pharmaceutical-co-ltd/ Fri, 17 Dec 2021 06:09:09 +0000 https://imisite.org/carlyle-reaches-definitive-agreement-for-sale-of-sunsho-pharmaceutical-co-ltd-to-towa-pharmaceutical-co-ltd/ Tokyo, Japan, December 17, 2021 – CJP SP Holding, LP, an investment fund operated and managed by global investment firm Carlyle (NASDAQ: CG), signed an agreement to sell 100% of its investment in Sunsho Pharmaceutical Co., Ltd. (“Sunsho Pharmaceutical “), a health and nutrition (” H&N “) and pharmaceutical manufacturing company contract, to Towa Pharmaceutical Co., Ltd. (“Towa Pharmaceutical”), a company engaged in the research and development, production and marketing of generic drugs. The transaction is expected to close in February 2022.

Based in Shizuoka, Sunsho Pharmaceutical is one of the largest contract manufacturers in Japan of soft capsules, seamless capsules and other dosage forms for pharmaceutical and H&N use. The company is focused on producing absolute quality products and applying cutting edge contract manufacturing technology to create cutting edge formulations and capsules.

CJP SP Holding, LPacquired a 100% stake in Sunsho Pharmaceutical in August 2014 through Carlyle’s third buyout fund in Japan, Carlyle Japan Partners III, after recognizing the strong growth potential of the company as a subcontractor on a H&N market in constant growth in Japan. Carlyle also saw the potential for value creation with Sunsho Pharmaceutical and in the H&N market in Japan by leveraging the knowledge of her local team, the strengths of her global platform and her deep experience in the healthcare industries. and consumption.

Through the ownership of Carlyle, Sunsho Pharmaceutical has strengthened its management structure and governance, initiated the launch of a new factory and research and development center to improve production capacities, diversified its portfolio of activities to meet new customers and has significantly increased its global revenues by strengthening and expanding its overseas business. Carlyle has also worked closely with the Sunsho Pharmaceutical leadership team to help drive innovation and co-create new value-added products and solutions with customers.

Carlyle will transfer full ownership to Towa Pharmaceutical to support Sunsho Pharmaceutical’s next phase of growth.

Carlyle has made 31 investments in Japan since entering the market in 2000 and this will be the 20th release to date. Carlyle has a well-established history of investing in the healthcare industry, both in Japan and around the world, investing more than US $ 14.7 billion in equity in more than 80 transactions in the global healthcare industry. healthcare as of September 30, 2021. Investments in healthcare in Japan include Qualicaps Co., Ltd. and Solasto Corporation.

***

About Carlyle

Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital in three business segments: Global Private Equity, Global Credit and Global Investment Solutions. With $ 293 billion in assets under management as of September 30, 2021, Carlyle’s goal is to invest wisely and create value on behalf of its investors, the companies in its portfolio and the communities in which we live. and let’s invest. Carlyle employs more than 1,800 people in 26 offices on five continents.

More information is available at www.carlyle.com. Follow Carlyle on Twitter @OneCarlyle.

About Sunsho Pharmaceutical

Sunsho Pharmaceutical is a company which plans, develops and carries out under contract the manufacture of H&N and pharmaceutical products, being a major player in the H&N market in Japan. Sunsho Pharmaceutical has complete factories in Shizuoka and offers contract manufacturing and packaging of soft capsules, seamless capsules and other dosage forms. In addition to manufacturing capacity and technology, Sunsho Pharmaceutical has first-class capability in R&D technology, sales force and quality control system. The company has various certificates including cGMP, GMP and HACCP. The company was founded in 1993 and currently employs 690 people.

For more information, visit the company’s website at: https://www.sunsho.co.jp/en/

Media contacts:

Carlyle
Lonna leong
+852 9023 1157
lonna.leong@carlyle.com

Kekst CNC
Jochen Legewie / Minako Otani
+81 3 5156 0185 / +81 3 5156 0190
carlyle@kekstcnc.com

]]>
ROSEN, ADVISOR TO LEADING INVESTORS, Encourages BioMarin Pharmaceutical Inc. Investors With Losses Over $ 100,000 To Obtain Legal Advice Before Important Dec. 22 Deadline in Securities Class Action – BMRN | national news https://imisite.org/rosen-advisor-to-leading-investors-encourages-biomarin-pharmaceutical-inc-investors-with-losses-over-100000-to-obtain-legal-advice-before-important-dec-22-deadline-in-securities-class-action/ Wed, 15 Dec 2021 03:09:00 +0000 https://imisite.org/rosen-advisor-to-leading-investors-encourages-biomarin-pharmaceutical-inc-investors-with-losses-over-100000-to-obtain-legal-advice-before-important-dec-22-deadline-in-securities-class-action/

NEW YORK, December 14, 2021 / PRNewswire / –

WHY: Rosen Law Firm, a global investor rights law firm, reminds buyers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021, inclusive (the “Recourse Period”), 22 December 2021 lead applicant time limit.

SO WHAT: If you purchased BioMarin securities during the Class Period, you may be entitled to compensation without payment of any costs or reimbursable charges through a contingency fee agreement.

WHAT TO DO NEXT: To join the BioMarin class action lawsuit, go to http://www.rosenlegal.com/cases-register-2185.html or call Phillip Kim, Esq. toll free at 866-767-3653 or by emailing pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action has already been filed. If you wish to act as the principal applicant, you must apply to the Court not later than 22 December 2021. A principal plaintiff is a representative party acting on behalf of the other members of the class to direct the litigation.

WHY THE ROSEN LAW: We encourage investors to select qualified advisors with a track record of success in leadership roles. Often, companies providing reviews do not have comparable experience, resources or peer recognition. Many of these companies do not actually litigate class actions in securities. Be wise in choosing a lawyer. Rosen law firm represents investors around the world, focusing its practice on class actions in securities and derivative litigation between shareholders. Rosen law firm has secured the largest securities class action settlement against a Chinese company. Rosen law firm was ranked # 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds millions of dollars for investors. In 2019 alone, the company achieved more than $ 438 million for investors. In 2020, founding partner Laurence Rosen has been named by law360 as Titan of the Plaintiff’s Bar. Many of the firm’s lawyers have been recognized by Lawdragon and Super Lawyers.

CASE DETAILS: According to the lawsuit, defendants throughout the litigation period made false and / or misleading statements and / or failed to disclose that: (1) BMN 307, an AAV5-mediated gene therapy, was less safe than BioMarin had led investors to believe; (2) The safety profile of BMN 307 made it likely that the United States Food and Drug Administration (FDA) would put a clinical suspension on the Phearless Phase 1/2 study; (3) as a result, BioMarin overestimated the clinical and commercial prospects of BMN 307; and (4) accordingly, the defendants’ public statements were materially false and misleading at all material times. When the real details entered the market, the lawsuit claims that investors have suffered damage.

To join the BioMarin class action lawsuit, go to http://www.rosenlegal.com/cases-register-2185.html or call Phillip Kim, Esq. toll free at 866-767-3653 or by emailing pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No class has been certified. Until a group is certified, you are not represented by a lawyer unless you hire one. You can choose the lawyer of your choice. You can also remain an absent group member and do nothing at this point. The ability of an investor to participate in any potential future payback does not depend on whether he is a principal applicant.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Lawyer advertising. Previous results do not guarantee a similar result.

Contact details:

Laurence Rosen, Esq.

Phillip Kim, Esq.

Rosen Law Firm, Pennsylvania

275 Madison Avenue, 40th Floor

New York, New York State 10016

Phone. : (212) 686-1060

Toll free: (866) 767-3653

Fax: (212) 202-3827

lrosen@rosenlegal.com

pkim@rosenlegal.com

cases@rosenlegal.com

www.rosenlegal.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/rosen-top-ranked-investor-counsel-encourages-biomarin-pharmaceutical-inc-investors-with-losses-in-excess -of -100k-to-secure-a-advice-before-the-important-December-22-deadline-in-the-classic-recourse-in-titles – bmrn-301444750.html

SOURCE Rosen Law Firm, PA

]]>
Zacks: Brokerages Anticipe Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) to announce – $ 0.04 BPA https://imisite.org/zacks-brokerages-anticipe-diffusion-pharmaceuticals-inc-nasdaq-dffn-to-announce-0-04-bpa/ Mon, 13 Dec 2021 06:24:23 +0000 https://imisite.org/zacks-brokerages-anticipe-diffusion-pharmaceuticals-inc-nasdaq-dffn-to-announce-0-04-bpa/

Brokerages expect Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) to post earnings per share of ($ 0.04) for the current fiscal quarter, reports Zacks Investment Research. No analyst has made any estimates on Diffusion Pharmaceuticals’ earnings. Diffusion Pharmaceuticals reported earnings of ($ 0.06) per share for the same quarter last year, suggesting a positive year-over-year growth rate of 33.3%. The company is expected to release its next results on Wednesday March 16.

According to Zacks, analysts expect Diffusion Pharmaceuticals to report annual earnings of ($ 0.22) per share for the current year, with EPS estimates ranging from $ 0.26 to $ 0.17. For the next fiscal year, analysts expect the company to post earnings of ($ 0.17) per share, with EPS estimates ranging from $ 0.17 to $ 0.16. Zacks Investment Research earnings per share averages are an average based on a survey of research analysts who cover Diffusion Pharmaceuticals.

Diffusion Pharmaceuticals (NASDAQ: DFFN) last released its quarterly results on Wednesday, November 10. The company reported ($ 0.12) EPS for the quarter, missing analyst consensus estimates of ($ 0.04) by ($ 0.08).

Several hedge funds and other institutional investors have recently changed their holdings in the company. Geode Capital Management LLC increased its stake in Diffusion Pharmaceuticals shares by 6.7% during the third quarter. Geode Capital Management LLC now owns 858,408 shares of the company valued at $ 437,000 after purchasing an additional 54,118 shares in the last quarter. Virtu Financial LLC increased its stake in Diffusion Pharmaceuticals shares by 86.1% during the second quarter. Virtu Financial LLC now owns 285,621 shares of the company valued at $ 209,000 after purchasing an additional 132,157 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of Diffusion Pharmaceuticals during the second quarter valued at approximately $ 110,000. Millennium Management LLC acquired a new position in Diffusion Pharmaceuticals during the first quarter valued at approximately $ 307,000. Finally, State Street Corp purchased a new position in Diffusion Pharmaceuticals during the second quarter valued at approximately $ 336,000. Hedge funds and other institutional investors hold 9.79% of the company’s shares.

(A d)

We took out the complexities and translated Wall Street into English. If you are new to options trading, this guide is for you!

NASDAQ: DFFN opened at $ 0.38 on Monday. The stock has a market cap of $ 38.84 million, a price-to-earnings ratio of -1.36 and a beta of 1.49. The company has a fifty-day simple moving average of $ 0.43 and a two hundred-day simple moving average of $ 0.55. Diffusion Pharmaceuticals has a 12-month low of $ 0.34 and a 12-month high of $ 1.85.

Diffusion Pharmaceuticals Company Profile

Diffusion Pharmaceuticals, Inc. is a clinical stage company engaged in the development of treatments for life-threatening conditions. It offers trans sodium crocetinate. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, Virginia.

Recommended story: How are outstanding shares different from authorized shares?

Get a Free Copy of Zacks’ Research Report on Diffusion Pharmaceuticals (DFFN)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Diffusion Pharmaceuticals now?

Before you consider Diffusion Pharmaceuticals, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts are quietly asking their clients to buy now before the broader market takes hold … and Diffusion Pharmaceuticals was not on the list.

While Diffusion Pharmaceuticals currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

]]> Individual investors represent 42% of the ownership of CSPC Pharmaceutical Group Limited (HKG: 1093), while institutions represent 28% https://imisite.org/individual-investors-represent-42-of-the-ownership-of-cspc-pharmaceutical-group-limited-hkg-1093-while-institutions-represent-28/ Fri, 10 Dec 2021 22:21:49 +0000 https://imisite.org/individual-investors-represent-42-of-the-ownership-of-cspc-pharmaceutical-group-limited-hkg-1093-while-institutions-represent-28/

A look at the shareholders of CSPC Pharmaceutical Group Limited (HKG: 1093) can tell us which group is more powerful. With 42% of the capital, individual investors hold the maximum number of shares in the company. That is, the group is most likely to benefit the most if the stock rises (or to lose the most if there is a decline).

Institutions, for their part, represent 28% of the company’s shareholders. Institutions often own shares in more established companies, while it is not uncommon to see insiders owning a good number of smaller companies.

Let’s take a closer look at each type of CSPC pharmaceutical group owner, starting with the table below.

Consult our latest analysis for the pharmaceutical group CSPC

SEHK: 1093 Distribution of ownership December 10, 2021

What does institutional ownership tell us about the pharmaceutical group CSPC?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it’s included in a major index. . We would expect most businesses to have some institutions listed, especially if they are growing.

The CSPC Pharmaceutical Group already has institutions registered in the share register. Indeed, they hold a respectable stake in the company. This suggests some credibility among professional investors. But we cannot rely on this fact alone because institutions sometimes make bad investments, like everyone else. If several institutions change their mind about a stock at the same time, you could see the stock price drop quickly. So it’s worth checking out the profit history of pharmaceutical group CSPC below. Of course, the future is what really matters.

profit and revenue growth
SEHK: 1093 Revenue and revenue growth on December 10, 2021

Hedge funds don’t have a lot of shares in CSPC Pharmaceutical Group. The company’s CEO, Dongchen Cai, is the largest shareholder with 23% of the shares outstanding. With 6.5% and 6.1% of shares outstanding, respectively, UBS Asset Management and Common Success International Limited are the second and third shareholders.

Looking at the register of shareholders, we can see that 50% of the property is controlled by the 12 major shareholders, which means that no shareholder has a controlling interest in the property.

Institutional ownership research is a good way to assess and filter the expected performance of a stock. The same can be achieved by studying the feelings of analysts. Many analysts cover the stock, so it can be interesting to see what they are forecasting as well.

Insider property of the pharmaceutical group CSPC

The definition of business insiders can be subjective and vary from jurisdiction to jurisdiction. Our data reflects individual insiders, capturing at least board members. The management of the company manages the company, but the CEO will report to the board of directors, even if he is a member of the board.

Insider ownership is positive when it indicates that executives think like the real owners of the company. However, strong insider ownership can also confer immense power on a small group within the company. This can be negative in some circumstances.

It appears that insiders own a significant proportion of CSPC Pharmaceutical Group Limited. It is very interesting to see that the insiders have a significant HK $ 24 billion stake in this HK $ 103 billion company. It’s good to see this level of investment. You can check here if these insiders have bought recently.

General public property

The general public, generally individual investors, own 42% of the capital of CSPC Pharmaceutical Group. This size of ownership, while considerable, may not be enough to change company policy if the decision is not aligned with other large shareholders.

Owned by a private company

Our data indicates that private companies own 6.3% of the company’s shares. It is difficult to draw conclusions from this fact alone, so it is worth considering who owns these private companies. Sometimes insiders or other related parties have an interest in shares of a public company through a separate private company.

Next steps:

I find it very interesting to see who exactly owns a company. But to really understand better, we have to take other information into account as well.

I like to dive deeper on the performance of a company in the past. You can find the history of income and earnings in this detailed graphic.

But finally it’s the future, not the past, which will determine the success of the owners of this business. Therefore, we believe it is advisable to take a look at this free report showing whether analysts are predicting a better future.

NB: The figures in this article are calculated from data for the last twelve months, which refer to the 12-month period ending on the last date of the month of date of the financial statement. This may not be consistent with the figures in the annual report for the entire year.

This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts using only unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take into account your goals or your financial situation. Our aim is to bring you long-term, targeted analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price sensitive companies or qualitative documents. Simply Wall St has no position in any of the stocks mentioned.

]]>
Shanghai Fosun Pharmaceutical: An announcement has just been posted by the issuer in the Chinese section of this website, a corresponding version of which may or may not be posted in this section https://imisite.org/shanghai-fosun-pharmaceutical-an-announcement-has-just-been-posted-by-the-issuer-in-the-chinese-section-of-this-website-a-corresponding-version-of-which-may-or-may-not-be-posted-in-this-section/ Thu, 09 Dec 2021 11:02:08 +0000 https://imisite.org/shanghai-fosun-pharmaceutical-an-announcement-has-just-been-posted-by-the-issuer-in-the-chinese-section-of-this-website-a-corresponding-version-of-which-may-or-may-not-be-posted-in-this-section/

Shanghai Fosun Pharmaceutical : An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section [date] https://www.marketscreener.com/quote/stock/SHANGHAI-FOSUN-PHARMACEUT-6548924/news/Shanghai-Fosun-Pharmaceutical-An-announcement-has-just-been-published-by-the-issuer-in-the-Chinese-37261659/ [market] [doc type] [stock code] [stock name]

An announcement has just been posted by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section.

12/09/2021 6:58 PM

Connect

SEHK

htm

02196

FOSUN PHARMA

NOTICE OF AN EXTRAORDINARY GENERAL MEETING

12/09/2021 6:58 PM

Connect

SEHK

pdf

00107

SICHUAN EXPRESS

PROPOSAL TO CONSOLIDATE THE SHARES, PROPOSAL TO CHANGE THE SIZE OF THE BOARD LOT AND NOTICE OF A SPECIAL GENERAL MEETING

12/09/2021 6:57 PM

Connect

SEHK

pdf

01141

CMBC CAPITAL

LIST OF DIRECTORS AND THEIR ROLES AND DUTIES

12/09/2021 6:55 PM

Connect

SEHK

pdf

06878

DIFFERENT GROUP

NOTICE OF THE SECOND EXTRAORDINARY GENERAL MEETING 2021

12/09/2021 6:54 PM

Connect

SEHK

pdf

06806

SWHY

Next day disclosure return

12/09/2021 6:53 PM

Connect

SEHK

pdf

00960

LONGFOR GROUP

APPOINTMENT OF THE DIRECTOR GENERAL

12/09/2021 6:52 PM

Connect

SEHK

pdf

06878

DIFFERENT GROUP

FOREIGN REGULATORY NOTICE – China International Marine Containers (Group) Co., Ltd. Independent Opinions of Independent Directors of the Ninth Session of the Board of Directors regarding related transactions / related party transactions pending with Sinotrans & CSC Holdings Co., Ltd.

12/09/2021 6:51 PM

Connect

SEHK

pdf

02039

CIMC

(1) CONTINUOUS RELATED TRANSACTION AND (2) NOTICE OF MEETING OF THE EXTRAORDINARY GENERAL MEETING

12/09/2021 6:50 PM

Connect

SEHK

pdf

00107

SICHUAN EXPRESS

SURVEY RESULTS OF THE EXTRAORDINARY GENERAL MEETING OF DECEMBER 9, 2021

12/09/2021 6:49 PM

Connect

SEHK

pdf

02255

HAICANG HLDG

SURVEY RESULTS OF THE EXTRAORDINARY GENERAL MEETING OF DECEMBER 9, 2021

12/09/2021 6:48 PM

Connect

SEHK

pdf

01233

TIMES CHINA

OPINION ON THE RESOLUTIONS OF THE TWENTY-NINTH MEETING IN 2021 OF THE NINTH SESSION OF THE COUNCIL

12/09/2021 6:47 PM

Connect

SEHK

pdf

02039

CIMC

Next day disclosure return

12/09/2021 6:46 PM

Connect

SEHK

pdf

02899

ZIJIN MINING

An announcement has just been posted by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section.

12/09/2021 6:45 PM

Connect

SEHK

htm

00811

XINHUA WINSHARE

JOINT OPINION (1) PROPOSAL FOR PRIVATIZATION OF GOOD FRIEND INTERNATIONAL HOLDINGS INC. BY THE OFFERER BY MEANS OF A SCHEME OF ARRANGEMENT (UNDER ARTICLE 86 OF THE COMPANIES ACT) (2) SANCTION OF THE SCHEME BY THE GRAND COURT (3) WHEREAS THE SCHEME COMES INTO FORCE AND (4) PROPOSED WITHDRAWAL OF REGISTRATION

12/09/2021 6:44 PM

Connect

SEHK

pdf

02398

GOOD FRIEND

Next day disclosure return

12/09/2021 6:44 PM

Connect

SEHK

pdf

00327

WORLD PAX

Notification letter and request form to non-registered shareholders

12/09/2021 6:40 PM

Connect

SEHK

pdf

01922

YINCHENG LS

Notification letter and modification request form to registered shareholders

12/09/2021 6:38 PM

Connect

SEHK

pdf

01922

YINCHENG LS

Announcement of the results of the allocation of the reserved portion under the A Restricted Action Incentive Program for 2020

12/09/2021 6:38 PM

Connect

SEHK

pdf

02899

ZIJIN MINING

An announcement has just been posted by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section.

12/09/2021 6:38 PM

Connect

SEHK

htm

06178

EB SECURITIES

Disclaimer

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published this content on 09 December 2021 and is solely responsible for the information it contains. Distributed by Public, unedited and unmodified, on 09 December 2021 11:01:02 AM UTC.

Public now 2021

All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

Sales 2021 36,295 million
5,720 million
5,720 million
Net income 2021 4,480 million
706 million
706 million
Net debt 2021 14 452 million
2,278 million
2,278 million
PER 2021 ratio 30.0x
Yield 2021 0.88%
Capitalization 121 B
19,003 M
18,999 million
VE / Sales 2021 3.72x
VE / Sales 2022 3.08x
Number of employees 32 258
Free float 58.1%

Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration :

Period:

Technical analysis chart of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.  |  MarketScreener

Technical Analysis Trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

Short term Mid Road Long term
Tendencies Neutral Bearish Neutral

Evolution of the income statement

To sell

To buy

Average consensus SURPASS
Number of analysts 11
Last closing price

51.80 CNY

Average price target

68.65 CNY

Spread / Average target 32.5%

]]>
Pharmaceutical intermediates market to reach $ 37,290.33 million by 2028, according to The Insight Partners https://imisite.org/pharmaceutical-intermediates-market-to-reach-37290-33-million-by-2028-according-to-the-insight-partners/ Tue, 07 Dec 2021 09:30:00 +0000 https://imisite.org/pharmaceutical-intermediates-market-to-reach-37290-33-million-by-2028-according-to-the-insight-partners/

Pharmaceutical intermediates market

Pharmaceutical Intermediates Market Expected to Grow at a CAGR of 4.2% to Reach US $ 37,290.33 Million from 2020 to 2028

NEW YORK, UNITED STATES, Dec. 7, 2021 /EINPresswire.com/ – According to new research from The Insight Partners on “Pharmaceutical Intermediates Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type , Applications and Distribution Channel “The report highlights the prevailing trends in the market as well as the drivers and obstacles related to the market growth. Factors such as the increasing prevalence of chronic diseases and infectious diseases, and increasing investments by pharmaceutical companies in R&D activities are fueling the market growth. However, the high cost of manufacturing the drugs is the major factor hampering the growth of the market.

Strategic perspectives

Report Coverage (Details)
Market size value in – US $ 27,356.70 million in 2020
Market size value of – US $ 37,290.33 million by 2028
Growth rate – CAGR of 4.2% from 2021-2028
Forecast period – 2021-2028
Baseline year – 2021
Number of Pages – 185
Number of tables – 84
Number of graphs and figures – 72
Historical data available – Yes
Segments Covered – Type; Applications; Distribution channel and geography
Regional scope – North America; Europe; Asia Pacific; Latin America; AEM
Country Scope – US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina
Report Cover – Revenue Forecast, Company Rank, Competitive Landscape, Growth Factors & Trends

Get Sample PDF Copy of Pharmaceutical Intermediates Marketplace at: https://www.theinsightpartners.com/sample/TIPRE00005559/

Growing prevalence of chronic diseases and infectious diseases

Pharmaceutical intermediates are the building blocks of active pharmaceutical ingredients (APIs). These are raw materials that undergo molecular change or processing during the production of bulk drugs. Thus, the need for pharmaceutical intermediates increases with the increasing demand for drugs to treat chronic diseases. According to the Centers for Disease Control and Prevention (CDC), 6 in 10 adults in the United States suffer from at least one chronic disease such as cancer, heart disease, lung disease, stroke, neurological disease, diabetes and kidney disease. In addition, 4 in 10 adults in the country suffer from two or more chronic diseases. In addition, according to the press release from the European Alliance of Chronic Diseases (ECDA), in 2014, 9 out of 10 people in Europe died from chronic diseases. Thus, 70 to 80% of total health expenditure is devoted to the management of chronic diseases.

The increasing prevalence of infectious diseases, especially in Southeast Asia, is also likely to propel the demand for APIs in the coming years, eventually leading to the growth of the pharmaceutical intermediates market. For example, according to the revised report of the National Tuberculosis Control Program, around 4.4 lakh of patients died from tuberculosis in India in 2018, or 29% of the total 1.5 million deaths caused by tuberculosis. disease in the world. Thus, such a high prevalence of chronic diseases and infectious diseases reinforces the demand for drugs, ultimately highlighting the need for pharmaceutical intermediates.

COVID-19 started in Wuhan, China in December 2019 and since then it has spread at a rapid rate across the world. The United States, India, Brazil, Russia, France, United Kingdom, Turkey, Italy and Spain are among the most affected countries in terms of confirmed cases and reported deaths. COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans and business closures.

Download the latest COVID-19 Analysis on Pharmaceutical Intermediates Market Growth Research Report at: https://www.theinsightpartners.com/covid-analysis-sample/TIPRE00005559?utm_source=EINPressWire&utm_medium=10144

The pharmaceutical intermediates market, by type, is segmented into GMP and non-GMP. GMP segment held the largest share of the market in 2020, while the same segment is expected to register the highest CAGR of 4.4% in the market during the forecast period.

The Pharmaceutical Intermediates market, by application, is segmented with Antibiotics, Antipyretic Pain relievers, Vitamins, and others. The antibiotics segment held the largest share of the market in 2020, and this segment is also expected to register the highest CAGR of 4.9% in the market during the forecast period.

On the basis of distribution channel, the pharmaceutical intermediates market has been segmented into distributor and direct sales. The direct sales segment held the largest share of the market in 2020, and the distributor segment is expected to register the highest CAGR of 4.2% in the market during the forecast period.

Pharmaceutical intermediates market: competitive landscape and key developments

Pfizer Inc.,.; Sanofi,; BASF SE,; Lianhe Chemical Technology Co., Ltd; Dishman Carbogen Amcis Ltd,; Codexis,; Midas Pharma GmbH,; chiracon GmbH,; Dextra Laboratories Limited,; and Vertellus Holdings LLC are among the leading companies operating in the mid-market pharmaceutical market.

Companies are adopting inorganic and organic growth strategies to expand their global footprint and product portfolio to meet growing demand for pharmaceutical intermediates. For example, in January 2021, Pritzker Private Capital, a leader in family direct investment, acquired the Vertellus group of companies, a manufacturer of specialty chemicals. Based in Indianapolis, Indiana, Vertellus is a leading supplier of specialty chemicals to the healthcare, personal care, food and agriculture, coatings and transportation markets.

Order a copy of the Research Report 202-20028 Growth, Strategy and Forecast of Pharmaceutical Intermediates Market at: https://www.theinsightpartners.com/buy/TIPRE00005559/

Browse related reports and get a sample copy

Pharmaceutical Solvents Market Forecast to 2028 – Impact of Covid-19 and Global Analysis – by Chemical Group (Alcohol, Amine, Esters, Ethers, Chlorinated Solvents, Others)
https://www.theinsightpartners.com/sample/TIPRE00005800/?utm_source=EINPressWire&utm_medium=10144

Pharmaceutical Excipients Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Product (Organic Chemicals, Inorganic Chemicals, and Other); Functionality (fillers and thinners, suspending and viscosity agents, coating agents, binders, preservatives, emulsifying agents and other functionalities); Formulation type (oral formulations, topical formulations, parenteral formulations and other formulations) and geography
https://www.theinsightpartners.com/sample/TIPRE00003534/?utm_source=EINPressWire&utm_medium=10144

About Us:
The Insight Partners is the industry’s unique research provider for actionable intelligence. We help our clients find solutions to their research needs through our syndicated research and advisory services. We specialize in industries such as Semiconductors & Electronics, Aerospace & Defense, Automotive & Transportation, Biotechnology, Health Informatics, Manufacturing & Construction, Medical Devices , technology, media and telecommunications, chemicals and materials.

Press Release: https://www.theinsightpartners.com/pr/pharmaceutical-intermediates-market
More research: https://daulatguru.com/author/theinsightpartners/

Sameer joshi
Insight partners
+91 96661 11581
write us here
Visit us on social networks:
Facebook
Twitter
LinkedIn

]]>
Karachi pharmaceutical companies ship free drugs worth Rs 25million to Afghanistan https://imisite.org/karachi-pharmaceutical-companies-ship-free-drugs-worth-rs-25million-to-afghanistan/ Sun, 05 Dec 2021 06:50:00 +0000 https://imisite.org/karachi-pharmaceutical-companies-ship-free-drugs-worth-rs-25million-to-afghanistan/

Keeping their promise to support and help the neighboring country, pharmaceutical companies in Pakistan have started providing free medicine to Afghanistan.

Two containers of drugs worth Rs 25 million left Karachi for Islamabad on Saturday, said Atif Iqbal, vice president of the Pakistan Pharmaceutical Manufacturing Association. Digital SAMAA. “Next week these drugs will be sent to Afghanistan. ”

He said the country’s goal is to deliver drugs costing Rs 1 billion to the war-torn country during the second week of December. “Medicines and other pharmaceutical equipment are also being sent to the capital from Peshawar, Lahore, Multan and other major cities,” Iqbal revealed.

He added that some international companies are also participating in this initiative.

Ghulam Hashim Noorani of the Pakistan Association of Chemists and Drug Addicts said that in addition to medicines, 400 wheelchairs were also being sent to the neighboring country.

“We buy drugs from the local market and will ship them with the shipment as well,” he said. Digital SAMAA. “This is the start and we hope our industry will come forward and meet the expectations of our Afghan friends. They desperately need our help.

Some of the companies supplying drugs to Karachi include Hico, PharmEvo, ICI Pakistan, Bosch Pharma, SEARLE, and MaxiTech Pharma.

Health care in Afghanistan on the brink of collapse

Earlier this year, the World Health Organization warned of a looming health crisis in Afghanistan.

“The country’s health system is on the brink of collapse as lack of funding has left thousands of health facilities struggling to purchase medical supplies and pay their staff.

WHO stressed that reduced donations to Afghanistan’s largest health project, Sehatmandi, left health facilities without drugs, medical supplies, fuel and salaries for medical staff.

Sehatmandi operates 2,309 medical facilities across Afghanistan benefiting more than 30 million people in 2020.

“Many of these facilities have now scaled back their operations or closed their doors, forcing health providers to make tough decisions about who to save and who to let die,” a WHO statement said, adding that only 17% of facilities were fully functional.

]]>
Zacks: Analysts expect Teva Pharmaceutical Industries Limited (NYSE: TEVA) to post earnings per share of $ 0.74 https://imisite.org/zacks-analysts-expect-teva-pharmaceutical-industries-limited-nyse-teva-to-post-earnings-per-share-of-0-74/ Fri, 03 Dec 2021 12:23:47 +0000 https://imisite.org/zacks-analysts-expect-teva-pharmaceutical-industries-limited-nyse-teva-to-post-earnings-per-share-of-0-74/

Brokerages expect Teva Pharmaceutical Industries Limited (NYSE: TEVA) to post earnings of $ 0.74 per share for the current fiscal quarter, Zacks reports. Five analysts have released earnings estimates for Teva Pharmaceutical Industries, with estimates ranging from $ 0.67 to $ 0.81. Teva Pharmaceutical Industries reported earnings of $ 0.68 per share in the same quarter last year, suggesting a positive year-over-year growth rate of 8.8%. The company is expected to release its next quarterly earnings report on Wednesday, February 9.

According to Zacks, analysts expect Teva Pharmaceutical Industries to report annual earnings of $ 2.56 per share for the current fiscal year, with EPS estimates ranging from $ 2.48 to $ 2.62. For the next fiscal year, analysts predict the company will post earnings of $ 2.68 per share, with EPS estimates ranging from $ 2.57 to $ 2.72. Zacks’ BPA calculations are an average based on a survey of seller-side research analysts who follow Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries (NYSE: TEVA) last released its quarterly results on Wednesday, October 27. The company reported EPS of $ 0.59 for the quarter, missing Zacks’ consensus estimate of $ 0.65 ($ 0.06). Teva Pharmaceutical Industries had a net margin of 4.47% and return on equity of 23.53%. The company posted revenue of $ 3.89 billion for the quarter, compared to $ 4.05 billion expected by analysts. During the same period of the previous year, the company posted earnings per share of $ 0.56. The company’s turnover is down 2.8% compared to the same quarter last year.

(A d)

Geologists predict that Nevada could hold 25% of the world’s lithium supply. And with lithium quickly becoming the most precious (and important) metal on the planet, Nevada could quickly become one of the wealthiest states in the United States …

TEVA has been the subject of several analyst reports. Raymond James downgraded Teva Pharmaceutical Industries from an “outperformance” rating to a “market performance” rating in a report released on Thursday, October 28. TheStreet downgraded Teva Pharmaceutical Industries from a “d +” rating to a “c” rating in a report released on Wednesday, October 27. Four research analysts rated the stock with a conservation rating. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $ 11.50.

A number of hedge funds have recently changed their holdings to TEVA. Patriot Financial Group Insurance Agency LLC increased its stake in shares of Teva Pharmaceutical Industries by 196.2% during the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 4,100 shares of the company valued at $ 41,000 after purchasing an additional 2,716 shares in the last quarter. Ayalon Holdings Ltd. increased its stake in the shares of Teva Pharmaceutical Industries by 86.0% in the second quarter. Ayalon Holdings Ltd. now owns 4,267 shares of the company valued at $ 42,000 after acquiring an additional 1,973 shares during the last quarter. Carolina Wealth Advisors LLC increased its stake in the shares of Teva Pharmaceutical Industries by 18.5% in the 2nd quarter. Carolina Wealth Advisors LLC now owns 7,441 shares of the company valued at $ 74,000 after acquiring 1,161 additional shares during the last quarter. Samalin Investment Counsel LLC purchased a new position in Teva Pharmaceutical Industries shares in the second quarter valued at approximately $ 86,000. Finally, Sigma Planning Corp bought a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter for a value of approximately $ 98,000. Institutional investors and hedge funds hold 50.60% of the company’s shares.

NYSE: TEVA opened at $ 8.16 on Friday. The company has a market cap of $ 9.00 billion, a P / E ratio of 12.36, a P / E / G ratio of 1.06 and a beta of 1.28. Teva Pharmaceutical Industries has a one-year low at $ 8.03 and a one-year high at $ 13.30. The company has a debt to equity ratio of 1.84, a current ratio of 1.03, and a quick ratio of 0.68. The company has a fifty-day simple moving average of $ 9.37 and a two hundred-day simple moving average of $ 9.64.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. is dedicated to the development and production of drugs. Its products include drugs for cardiovascular disease, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, as well as colds and coughs. The company operates in the following geographic segments: North America, Europe and international markets.

Featured article: How to start trading in the forex market?

Get a Free Copy of Zacks’ Teva Pharmaceutical Industries (TEVA) Research Report

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Historical and earnings estimates for Teva Pharmaceutical Industries (NYSE: TEVA)

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Teva Pharmaceutical Industries now?

Before you consider Teva Pharmaceutical Industries, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts are quietly asking their clients to buy now before the broader market takes hold of … and Teva Pharmaceutical Industries was not on the list.

While Teva Pharmaceutical Industries currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here

]]> Noma Al-Ahmad – The Pharmaceutical Journal https://imisite.org/noma-al-ahmad-the-pharmaceutical-journal/ Wed, 01 Dec 2021 13:06:10 +0000 https://imisite.org/noma-al-ahmad-the-pharmaceutical-journal/

The seeds of what would become Noma Al-Ahmad’s mission were sown early in his career, with a disastrous pre-registration placement at an independent pharmacy.

“It was a bunch of lies and they weren’t determined to train at all,” Al-Ahmad said.

After months of doing nothing but boxes of pods, the General Pharmaceutical Council (GPhC) offered little help. She tried to look for an alternative, but no one was interested. It’s very difficult for interns in this position, says Al-Ahmad, “you’re kind of blacklisted.”

Eventually her persistence paid off and she was able to complete her training at another pharmacy, but the experience stuck with her. Insisting that no other trainee should undergo the same ordeal, she set herself the goal of considerably improving the training offered.

After graduating, she founded ProPharmace in 2006, today one of the UK’s leading pharmacy training providers. Almost 15 years later, it has grown from an initial cohort of 20 trainees to now 500 trainees per year, offering courses in setting up an immunization clinic, mock exams and training for supervisors.

“Her work in improving the quality of pre-registration training has had an impact nationwide by transforming the way pharmacy managers design and deliver their training programs,” said his proponent.

In September 2020, his team won a contract with Health Education England (HEE) to train supervisors for the London and South East region. In March 2021, this was extended to the south of England.

We want trainee pharmacists never to go through what I had to

“If supervisors know what they are doing and can provide effective training and be certified, trainees are more likely to have a good experience,” says Al-Ahmad. “We want trainee pharmacists never to experience what I had to do. “

She would like the GPhC to make this training compulsory for all supervisors. At the moment, it is only mandatory for services ordered by HEE.

As Managing Director, Al-Ahmad supervises a small team of ten internal employees and around thirty trainers. The size of their business means they can be flexible, she notes. “We are always trying to stay ahead and adapt,” says Al-Ahmad. A perfect example was the sudden need to switch to online training from face-to-face sessions during the COVID-19 pandemic.

“When the GPhC announced that its exams would be posted online, it took a long time for them to announce it, but we were ready for it and had prepared online practice exams in advance,” says Al-Ahmad. .

ProPharmace has also created a set of free training resources to help pharmacy teams and some universities have reached out to ask for help.

The program is constantly evolving alongside the profession, she says, and recently there has been a lot of work devoted to introducing vital clinical skills sessions to new core pharmacy programs.

What sets Al-Ahmad apart, according to the person who appointed him, is his quickness in reaching out and supporting interns through difficult times. It offers tailor-made and free support to students in case of need, including those who have had difficulties with visas and refugee pharmacists..

The impact of the work that has been done to date can be seen in the high success rates of their interns, she notes. “We also always take feedback after each session into account so that we can adapt,” she adds.

For now, Al-Ahmad is focusing only on business, as well as her role as a guest lecturer at King’s College London (KCL). She is working on training collaborations with several universities, including KCL, as they learn about new basic pharmacy programs. “I would like to return to work in pharmacy next year as a substitute,” she says. “It is important to keep in touch. I plan to do my independent prescription and return to another area.

Starting her own business has been a learning curve, she admits: “Throughout my career, men have told me that we want to work with you because we think we can do better and that has been a challenge for me to navigate. “My advice to women who want to start a business is to go out there and not be stopped by someone who says you can’t do it. It can be hard to be taken seriously, but for me it’s about integrity and setting high standards. “

“Noma demonstrates that you can build on a passion to improve education and training and grow your business. “

“What is inspiring is the added value she puts into solving issues such as the black pharmacist level gap and supporting trainee pharmacists during one of the most difficult times of their careers. “

“Very influential. The work she does is very important and necessary. Tangible results.

Meet the rest of Pharmaceutical journalWomen to watch 2021 here

]]>
TRACON Pharmaceutical (TCON) announces regulatory approval of Envafolimab in China https://imisite.org/tracon-pharmaceutical-tcon-announces-regulatory-approval-of-envafolimab-in-china/ Mon, 29 Nov 2021 13:09:04 +0000 https://imisite.org/tracon-pharmaceutical-tcon-announces-regulatory-approval-of-envafolimab-in-china/

Receive instant alerts for news on your actions. Claim your 1-week free trial for Street Insider Premium here.


TRACON Pharmaceuticals (NASDAQ: TCON), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel, targeted cancer therapies and using a profitable, CRO-independent product development platform to partner with companies company to develop and market innovative products in the United States, today announced that its partners Alphamab Oncology (stock code: 9966.HK) and 3D Medicines (Beijing) Co., Ltd. announced that envafolimab (KN035), the world’s first single domain PD-L1 antibody formulated for subcutaneous injection, has received marketing authorization from the Chinese National Medical Products Administration (NMPA).

Envafolimab has been approved for use in adult patients with advanced solid tumors with high microsatellite instability (MSI-H) or MisMatch-deficient repair (dMMR), including patients with advanced colorectal cancer who have experienced progression of disease after treatment with fluoropyrimidine, oxaliplatin and irinotecan, as well as patients with other advanced solid tumors who have experienced disease progression after previous systemic therapy and have no satisfactory alternative treatment options.

Prior to this approval, all marketed PD-1 and PD-L1 antibody drugs required intravenous infusions. As a subcutaneously administered PD-L1 antibody, envafolimab can be administered within 30 seconds in the doctor’s office, increasing convenience, shortening the duration of treatment, and preventing patients from the risk of related reactions. to the infusion.

In a pivotal Phase 2 clinical study in patients with advanced dMMR / MSI-H tumors who received one or more lines of treatment, envafolimab demonstrated an objective response rate (ORR) by independent, blinded radiographic examination ( BIRR) by 44.7%, including 12 (11.7%) cases of complete response. Responses were durable, with a duration of response of 12 months in responder patients with advanced colorectal cancer (CRC), advanced gastric cancer, other advanced solid tumors and 89%, 100%, 100 % and 93%, respectively. . The median progression-free survival was 11.1 months and the 12-month overall survival rate was 73.6%. The BIRR-confirmed ORR in patients with MSI-H / dMMR CRC treated with envafolimab who failed fluoropyrimidine, oxaliplatin, and irinotecan was 32%, which was similar to the reported 28% of confirmed ORRs. in the OPDIVO® package leaflet in MSI-H / dMMR Patients with CRC who have failed fluoropyrimidine, oxaliplatin and irinotecan therapy and the confirmed 33% ORR reported for KEYTRUDA® in patients with MSI-H / dMMR CRCs who failed treatment with fluoropyrimidine, oxaliplatin and irinotecan in Cohort A of the Phase 2 KEYNOTE-164 trial. Envafolimab was well tolerated in this study and there were no reports of immune-related pneumonia, immune-related colitis or immune-related nephritis.

“We are delighted that the dedication of our partners Alphamab Oncology and 3D Medicines has resulted in the initial approval of the first subcutaneously administered checkpoint inhibitor,” said Charles Theuer, MD, Ph.D., president and CEO of TRACON. “It is important to note that the TRACON-sponsored ENVASARC pivotal trial of envafolimab for the treatment of pleomorphic undifferentiated sarcoma (UPS) and myxofibrosarcoma (MFS) in the United States continues to perform well at 26 sites, and we look forward to the Independent Data Monitoring Committee’s review. intermediate efficacy and safety data before the end of the year.

]]>